Home Cart Sign in  
Chemical Structure| 13739-02-1 Chemical Structure| 13739-02-1

Structure of Diacerein
CAS No.: 13739-02-1

Chemical Structure| 13739-02-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Diacerein is a symptomatic slow-acting medicine in osteoarthritis which can reduce the level of IL-1 receptors leading to fewer receptors to form heterodimer complexes.

Synonyms: Diacerhein; Diacetylrhein; SF 277

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Diacerein

CAS No. :13739-02-1
Formula : C19H12O8
M.W : 368.29
SMILES Code : O=C(C1=C2C(OC(C)=O)=CC=C1)C3=CC(C(O)=O)=CC(OC(C)=O)=C3C2=O
Synonyms :
Diacerhein; Diacetylrhein; SF 277
MDL No. :MFCD00468030
InChI Key :TYNLGDBUJLVSMA-UHFFFAOYSA-N
Pubchem ID :26248

Safety of Diacerein

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Chondrocytes 10 μmol/L 24 hours Modulated Wnt signaling, reduced release of matrix-degrading enzymes from chondrocytes, demonstrated anabolic activity in chondrocytes. PMC11628851
Chondrocytes 10 μmol/L 1, 3, 5 days Modulated Wnt signaling, reduced release of matrix-degrading enzymes from chondrocytes, demonstrated anabolic activity in chondrocytes. PMC11628851
Mouse primary hepatocytes 40 μM 30 min pretreatment, followed by LPS stimulation for 4 h and cholesterol stimulation for 12 h To evaluate the effect of CVC on CCL2-induced hepatocyte steatosis. CVC down-regulated the fatty acid synthesis gene Fasn and up-regulated the fatty acid oxidation genes Acox-1, Pgc1α, and Ucp-2. PMC9238089
Mouse Kuffer cells 40 μM 30 min pretreatment, followed by LPS stimulation for 4 h and cholesterol stimulation for 12 h Diacerein inhibited IL-1β secretion but had no effect on TNF-α; inhibited ASC speck formation PMC9238089
Mouse bone marrow-derived macrophages (BMDMs) 40 μM 30 min pretreatment, followed by LPS stimulation for 4 h and nigericin stimulation for 2 h To evaluate the effect of Phloretin on the inflammatory phenotype of macrophages, results showed that Phloretin reduces the inflammatory phenotype by activating the Nrf2 signaling pathway. PMC9238089

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Destabilized medial meniscus (DMM)-induced osteoarthritis model Intra-articular injection 2 mg/kg Once weekly for 3 weeks To evaluate the therapeutic effect of Diacerein nanoformulations on osteoarthritis. Results showed that Diacerein nanoformulations significantly improved joint degeneration, reduced cartilage damage, and alleviated pain. PMC11628851
C57BL/6 mice NAFLD model induced by methionine and choline deficiency diet (MCD) Gavage 15 mg Every 2 days for 3 weeks or 9 weeks Diacerein improved liver function (ALT and AST), serum inflammation (IL-1β and TNF-α), histopathological inflammation score, and liver fibrosis PMC9238089
Mice Partial infraorbital nerve ligation (pIONL)-induced trigeminal neuropathic pain Intra-trigeminal ganglion injection 5 μg Single injection Diacerein attenuated pIONL-induced orofacial pain PMC4940825
BALB/c mice Acetaminophen-induced hepatotoxicity model Intraperitoneal injection 20 mg/kg Single administration, total experimental period was 36 hours To evaluate the preventive and curative effects of Diacerein on acetaminophen-induced hepatotoxicity. Results showed that Diacerein significantly reduced biomarkers of liver dysfunction, oxidative stress, hepatocyte necrosis, and infiltration of neutrophils and macrophages whether administered 4 h before or 2 h after acetaminophen. Further, Diacerein counteracted acetaminophen-induced hepatocellular apoptosis by increasing Bcl-2 and decreasing Bax and caspase-3 expression levels. Moreover, DCN normalized hepatic TNF-α and significantly decreased NF-κB p65 expression. PMC8967791

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04351100 Ocular Surface Disease|Osteoar... More >>thritis|Diacerein Less << COMPLETED 2020-07-31 Faculty of medicine, Chulalong... More >>korn university, Bangkok, 10330, Thailand Less <<
NCT00440661 Osteoarthritis PHASE4 COMPLETED 2025-10-08 Rheumatologic Institut of Mont... More >>real, Montreal, Quebec, H2L1S6, Canada Less <<
NCT00445276 Knee Osteoarthritis PHASE4 COMPLETED 2025-09-06 Chu Trousseau, Tours, 37044, F... More >>rance Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.72mL

0.54mL

0.27mL

13.58mL

2.72mL

1.36mL

27.15mL

5.43mL

2.72mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories